190 filings
Page 6 of 10
8-K
kpy 2gu4j020
2 Feb 22
Clene Announces New Chief Financial Officer Morgan Brown
12:00am
424B3
f0nr0bj9amwee 4c
18 Jan 22
Prospectus supplement
4:07pm
8-K
6jahqggocpaex 6xy
18 Jan 22
Clene Nanomedicine’s Second Asset, CNM-ZnAg, Completes 50% Patient Enrollment in COVID-19 Trial
7:00am
EFFECT
1wq4dxt 83ns8d02p6j
14 Jan 22
Notice of effectiveness
12:15am
POS AM
6wzid8nn74ys69a en
7 Jan 22
Prospectus update (post-effective amendment)
4:01pm
8-K
wiibeo
17 Dec 21
Regulation FD Disclosure
12:00am
424B3
ft4726f6e1jfncmfwaf1
14 Dec 21
Prospectus supplement
4:48pm
424B3
87wx66p0l
14 Dec 21
Prospectus supplement
4:46pm
8-K
pbzqp5
14 Dec 21
Other Events
4:43pm
8-K
r1wl8uvpkpk
1 Dec 21
Clene Nanomedicine Presents Updated Data from RESCUE-ALS Phase 2 Study at 4th Annual ALS ONE Research Symposium
7:05am
8-K
ygp0w6
15 Nov 21
Clene Announces Completion of Patient Enrollment in the HEALEY ALS Platform Trial
12:00am
424B3
ekauc6bb1
10 Nov 21
Prospectus supplement
4:02pm
424B3
2haepnxvf4dqof 0ds27
10 Nov 21
Prospectus supplement
4:01pm
8-K
apqn5h28bfhqpdh7kl
9 Nov 21
Clene Reports Third Quarter 2021 Operating and Financial Highlights
7:01am
8-K
ccg2dyibmyo z5404wgr
2 Nov 21
Clene Nanomedicine Announces Top-Line Results from
7:04am
8-K
35365m3z534
14 Oct 21
Clene Nanomedicine Presents Blinded Interim Update from VISIONARY-MS and Positive Results from REPAIR-MS Phase 2 Clinical Trials
7:01am
8-K
3xoloqjr6oti
7 Oct 21
Regulation FD Disclosure
4:01pm
424B3
35at wg1emzbus
29 Sep 21
Prospectus supplement
5:07pm
424B3
2pvp2uph09pmp
29 Sep 21
Prospectus supplement
5:05pm